Abstract:Acetaminophen (APAP)-induced liver injury (AILI) is the leading cause of acute liver failure in the United States, but its impact on metabolism, therapeutic efficacy, and adverse drug reactions (ADRs) of co- and/or subsequent administered drugs are not fully investigated. The current work explored this field with a focus on the AILI-mediated alterations of cytochrome P450-mediated drug metabolism. Various levels of liver injury were induced in mice by treatment with APAP at 0, 200, 400, and 600 mg/kg. Severity of liver damage was determined at 24, 48, 72, and 96 hours by plasma levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), microRNA miR122, and tissue staining. The expression and activities of CYP3A11, 1A2, 2B10, 2C29, and 2E1 were measured. Sedation efficacy and ADRs of midazolam, a CYP3A substrate, were monitored after APAP treatment. ALT, AST, and miR122 increased at 24 hours after APAP treatment with all APAP doses, whereas only groups treated with 200 and 400 mg/kg recovered back to normal levels at 72 and 96 hours. The expression and activity of the cytochromes P450 significantly decreased at 24 hours with all APAP doses but only recovered back to normal at 72 and 96 hours with 200 and 400, but not 600, mg/kg of APAP. The alterations of cytochrome P450 activities resulted in altered sedation efficacy and ADRs of midazolam, which were corrected by dose justification of midazolam. Overall, this work illustrated a low cytochrome P450 expression window after AILI, which can decrease drug metabolism and negatively impact drug efficacy and ADRs. SIGNIFICANCE STATEMENT: The data generated in the mouse model demonstrated that expression and activities of cytochrome P450 enzymes and correlated drug efficacy and ADRs are altered during the time course of liver repair and regeneration after liver is injured by treatment with APAP. Dose justifications based on predicted changes of cytochrome P450 activities can achieve desired therapeutic efficacy and avoid ADRs. The generated data provide fundamental knowledge for translational research to drug treatment for patients during liver recovery and regeneration who have experienced AILI.

Long-term Acetaminophen Treatment Induced Liver Fibrosis in Mice and the Involvement of Egr-1.

The effect of histone deacetylase inhibitor ACY1215 on the inflammatory response in mice with acute liver failure

[Protective Effects and Possible Mechanisms of Hepatic Fibrosis Against APAP-induced Lethal Injury].

Egr1 Confers Protection Against Acetaminophen‑induced Hepatotoxicity Via Transcriptional Upregulating of Acaa2.

Bifidobacterium Longum R0175 Protects Mice Against APAP-induced Liver Injury by Modulating the Nrf2 Pathway.

EGR1 is Crucial for the Chlorogenic Acid–provided Promotion on Liver Regeneration and Repair after APAP-induced Liver Injury

Hepatocyte-specific Mas Activation Enhances Lipophagy and Fatty Acid Oxidation to Protect Against Acetaminophen-Induced Hepatotoxicity in Mice

Inhibiting Hepatocyte Uric Acid Synthesis and Reabsorption Ameliorates Acetaminophen-Induced Acute Liver Injury in Mice.

The change of p62-keap1-Nrf2 signaling pathway in acetaminophen-induced acute liver injury

Natural Product Andrographolide Alleviated APAP-induced Liver Fibrosis by Activating Nrf2 Antioxidant Pathway

Integrative Proteomics and Immunochemistry Analysis of the Factors in the Necrosis and Repair in Acetaminophen-Induced Acute Liver Injury in Mice.

Acetaminophen-induced hepatotoxicity predominantly via inhibiting Nrf2 antioxidative pathway and activating TLR4-NF-κB-MAPK inflammatory response in mice

The TGFβ1 Receptor Antagonist GW788388 Reduces JNK Activation and Protects Against Acetaminophen Hepatotoxicity in Mice

Mesencephalic astrocyte-derived neurotrophic factor reprograms macrophages to ameliorate acetaminophen-induced acute liver injury via p38 MAPK pathway

Growth differentiation factor 15 is dispensable for acetaminophen-induced liver injury in mice

Intrabody Against Prolyl Hydroxylase 2 Ameliorates Acetaminophen-Induced Acute Liver Injury in Mice Via Concomitant Promotion of Angiogenesis and Redox Homeostasis.

Effect of GDF15 on acetaminophen (APAP)-induced liver injury in mice

Dynamic and coordinated regulation of KEAP1-NRF2-ARE and p53/p21 signaling pathways is associated with acetaminophen injury responsive liver regeneration.

Alterations of Cytochrome P450-Mediated Drug Metabolism during Liver Repair and Regeneration after Acetaminophen-Induced Liver Injury in Mice

CD5L deficiency attenuate acetaminophen-induced liver damage in mice via regulation of JNK and ERK signaling pathway

Post-treatment with Glycyrrhizin Can Attenuate Hepatic Mitochondrial Damage Induced by Acetaminophen in Mice